We're continuing to successfully deliver against our ESG commitments, with examples including:
- Supporting comprehensive and diverse clinical trials investigating a twice-yearly injectable for HIV prevention.
- Centering access and removing barriers to care: Our voluntary licensing programs provided access to 14.8 million HIV & HBV treatments and 8.3 million remdesivir-based treatments for COVID-19 in 2024. We also donated over $300 million in 2024 to global programs and partners aligned with our mission,
- Continuing to innovate for unmet needs including a therapy made available in 2024 for primary biliary cholangitis (PBC), a rare liver disease.
- Making significant progress toward ambitious energy reduction targets: surpassing our 2024 energy reduction KPI by 1.1 million kWh and realizing $1.8M in total energy cost savings/avoidance
Impact by the Numbers
14.8M
HIV and HBV treatments made available in 2024
781K
Healthcare providers educated through Gilead’s independent medical education program
271K
People reached with direct HIV services through RADIAN partnership in Eastern Europe and Central Asia since 2019
20M+
HIV and viral hepatitis tests conducted through Gilead’s FOCUS program since 2010
11.7K
Employee volunteer hours in 2024
$300M
Donated globally in 2024
Data updated annually. Next update scheduled for April 2026.